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Objectives: In this active control trial, the rate of radio-induced WHO
grade 3/4 oral mucositis and the change in quality of life, assessed by
OMWQ-HN, were measured in subjects with head and neck cancer
treated by platelet gel supernatant (PGS) and supportive medical
treatment versus subjects treated by supportive medical treatment
alone.
Materials and Methods: Eighty patients with nonmetastatic head and
neck cancer underwent curative or adjuvant radiotherapy. All patients
underwent supportive medical treatment and/or PGS at the beginning
and during radiotherapy. Sixteen patients received PGS in association
with supportive medical treatment. To obtain 2 groups virtually
randomized for important clinical characteristics subjects were
matched, by propensity analysis, with a group of subjects (64 patients)
treated with supportive medical treatment alone.
Results: Subjects treated with standard supportive treatment experi-
enced significant higher WHO grade 3/4 toxicity (55%; 35/64) than
subjects treated by PGS (13%; 3/16). The reduced toxicity found in
PGS group paralleled with the evidence that they developed later
symptoms with respect to controls. The Cox proportional hazard model
indicated that patients treated with standard supportive medical treat-
ment experienced 2.7-fold increase (hazard ratio = 2.7; 95% confidence
interval, 1.3-5.7) in the occurrence of WHO grade 3/4 toxicity. PGS
group significantly experienced higher quality of life than control
groups as measured by OMWQ-HN. A significant decrease in the
opioid analgesics usage was found in the PGS group.
Conclusions: These preliminary data should be interpreted with cau-
tion and could serve as a framework around which to design future
trials.
Key Words: oral mucositis, platelet gel supernatant, head and neck
cancer, radiotherapy, toxicity
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Radiation-induced oral mucositis (OM) is an acute compli-cation of patients with oropharynx, hypopharynx, and
salivary glands malignant tumors.1 Because of the OM severity
patients often stop feeding and, as consequence, they are forced
to receive nutrition through a gastrostomy tube or intravenous
line with a consequent weight loss1–3 and unplanned breaks
during radiotherapy (RT).4 To date, there are no standard
medical treatments that have proven a substantial preventive
action in RT-induced OM. Nutritional support, pain control, oral
decontamination, palliation of dry mouth, management of oral
bleeding, and therapeutic interventions based on the use of
cryotherapy, growth factors, anti-inflammatory agents, anti-
oxidants, and low-level laser therapy are currently used in OM
management with unsatisfying clinical results.5,6 Platelets, in
addition to regulating homeostasis, release several factors that
promote tissue repair, angiogenesis, and inflammation.7–11 On
the basis of this evidence, platelet supernatant, the supernatant
obtained after the activation of coagulation of platelet concen-
trate, has been used for the topical therapy of various clinical
conditions, including wounds and soft tissue injuries.11–20
Recently the platelet gel supernatant (PGS) was used on a
patient suffering from severe RT-induced OM that was unre-
sponsive to conventional supportive therapies. In this patient the
oral application PGS positively affected the course of radio-
induced OM.21 To the best of our knowledge, there is no sci-
entific evidence in literature investigating the use of oral PGS in
the management of chemoradio-induced OM in subjects suf-
fering from head and neck cancer (HNC). So, this study was
designed to examine the effects whether the addition of PGS to
standard supportive treatment can favorably affect clinical
management of radio-induced OM in subjects suffering from
HNC compared with standard supportive treatment alone.
MATERIALS AND METHODS
Patient Selection
In this active control trial, patients receiving RT with or
without chemotherapy for HNC and treated by PGS were
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prospectively recruited and compared with a historical pool of
patients selected by the propensity score analysis. This stat-
istical strategy allowed us to obtain 2 groups of patients vir-
tually randomized for important clinical characteristics (see the
Statistical methods section). Subjects with nonmetastatic, his-
tologically confirmed malignant neoplasm located in the oro-
pharynx, salivary glands, and oral cavity were included in this
study. Lymph node involvement was allowed. All patients
received curative or adjuvant RT, both as single treatment or in
association with chemotherapy. Other inclusion criteria
included: age 18 years and above; life expectancy >6 months;
adequate bone marrow, liver, and renal function based on
laboratory assessments performed within 7 days before start of
study treatment; negative serum or urine beta-HCG pregnancy
test within 7 days before the first administration of study
treatments for women of childbearing potential. Exclusion
criteria included: previous RT for carcinoma of the head and
neck; previous or concurrent cancer within 5 years before
study entry; and proven bacterial or fungal infection of the oral
cavity at the start of RT. The clinical characteristics of 2
groups matched by propensity analysis were shown in Table 1.
This pilot study was approved by the ethical committees of the
participating institution. Written informed consent was
obtained from each patient.
Supportive Medical Treatments
All patients were instructed to maintain the adequate
hydration and nutritional status by suggesting nonirritating,
nutrient dense foods and fluids accordingly with the nutritional
guidelines for mucositis symptoms management.22 Additional
measures (good oral hygiene, avoidance of spicy, acidic, hard,
and hot foods and beverages, use of mild-flavored toothpastes
and saline-peroxide mouthwashes 3 or 4 times per day, anti-
fungal agents) were used for minimizing OM. Patients
belonging to PGS group were instructed by researchers to use
PGS 3 times a day (1 hour before breakfast, lunch, and dinner),
including weekends, and to refrain from any oral intake for
30 minutes after dosing. Platelet suspension gel was prepared
as previously described.21,23 Patients were monitored during
the RT treatment and for the 7 weeks after the end of RT. All
supportive medical treatments including PGS were adminis-
tered beginning on the first day of RT or RT-chemotherapy
(CHT) course and was stopped at the end of radiation course.
Oncological Treatments
Irradiation was applied as 3D-conformal RT. For plan-
ning of the RT each patient received a computed tomographic
scan in an individually adjusted precision immobilization
device. In the definitive setting the gross tumor volume was
defined as the tumor and any nodes that were either: 1 cm or
more in short axis, necrotic, PET positive (where applicable),
or biopsy proven to contain tumor. A 5mm expansion was
added to create the clinical target volume (CTV) CTV70, with
a further 5mm to create the planning target volume (PTV)
PTV70 (dose of 70Gy in 35 fractions). An optional high-risk
nodal volume (CTV60) was defined for areas of uncertainty
(eg, suspicious nodes not meeting the criteria above). A 5mm
margin was added to create the PTV60, (dose of 60Gy in 30
fractions). A lower risk nodal volume (CTV50-54) was defined
to include the standard lymphatic drainage sites. A 5mm
margin was added to create the PTV50-54 (dose of 50 to 54Gy
in 25 to 27 fractions). In the adjuvant setting the highest,
intermediate, and the lower risk volumes were defined as for
definitive setting. The only difference with respect to curative
treatment was the dose delivered to the highest risk volume
that was of 66Gy. The treatments were conducted on a linear
accelerator (Elekta Sinergy) of 6 to 10MV with conventional
isocentric techniques. All plans were normalized to ensure that
95% of each PTV was covered by 95% of the prescription dose
for that volume. Daily cone-beam computed tomographic
scans was made during treatment to verify correct positioning
of patients before each RT fraction. Concurrent single-agent
cisplatin was the primary choice of chemotherapeutic agent.
Two regimens were used: 2 to 3 cycles (100mg/m2) of cisplatin
on days 1, 22, and 43 or intravenous cisplatin (40mg/m2)
administered weekly.
Assessment of Toxicity and Adverse Events
Starting with the first day of radiation treatment, 2 trained
evaluation team radiation-oncologists independently assessed
and documented the mucosal status grading the toxicity
according to WHO. When the score of toxicity was discordant
the 2 radiation-oncologists reviewed the specific case in con-
sensus. The assessment was performed 3 times weekly
(Monday, Wednesday, Friday) and intensified to daily
TABLE 1. Patients’ Characteristics After Propensity Matching
Analysis
Characteristics
PGS Group
(N= 16) (n
[%])
Control Group
(N= 64) (n [%]) P
Sex
Male 10 (62.5) 39 (61) 0.863
Female 6 (37.5) 25 (39)
Age (y)
Mean ± SD 56.2 ± 8.9 57.3 ± 6.1 0.560
Site
Oral cancer 6 (37.5) 21 (33) 0.846*
Oropharynx 5 (31.2) 25 (39)
Salivary gland 5 (31.2) 18 (28)
Histology
Squamous 12 (75) 43 (67.2) 0.810*
Adenocarcinoma 2 (12.5) 9 (14)
Mucoepidermoid
carcinomaw
2 (12.5) 12 (18.8)
Stage grouping
I 4 (25) 20 (31.2) 0.973*
II 5 (31) 18 (28.1)
III 4 (25) 20 (31.2)
IV 3 (19) 6 (9.5)
Radiotherapy
Adjuvant (Gy)
PTV1, 66z
PTV1, 60y
PTV2, 50-548
12 (75) 47 (73.4) 0.849
Definitive (Gy)
PTV1, 70z
PTV2, 60#
PTV3, 50-54**
4 (25) 17 (26.6)
Chemotherapyww
Yes 13 (81) 45 (70.3) 0.573
No 3 (19) 19 (29.7)
*Bonferroni adjustment for more than 2 comparisons.
wSalivary glands tumors.
zPTV1: high-risk region or postoperative bed.
yPTV1: intermediate-risk region.
8PTV1: lower risk region.
zPTV1: gross disease region.
#PTV1: high-risk subclinical region.
**PTV1: lower risk subclinical region.
wwPlatinum-based chemotherapy.
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inspection, when first signs of mucositis were noted by the
radiation-oncologists. Safety outcome measures also included
monitoring of treatment-emergent adverse events on physical
examination, vital signs, clinical laboratory safety tests, local
tolerability, and documentation of any serious adverse events
or deaths on the study.
Quality-of-Life Assessment
To assess the patients’ quality of life, a mucositis-specific
questionnaire already used to measure OM in subjects with
HNC (OMWQ-HN) was used as a comprehensive scale.24
Study Endpoints
The primary endpoint was to assess the efficacy of PGS in
association with standard supportive medical treatment com-
pared with standard supportive medical treatment alone in
reducing the risk for clinically significant OM (WHO grade
Z3) in patients receiving RT with or without chemotherapy.
The secondary endpoint was to compare the changes in
the quality of life among the patients treated by standard
supportive medical treatment or by standard supportive med-
ical treatments in association with PGS. For the primary end-
point the baseline assessment was set the first day of RT. For
the secondary endpoint the time frame for reference was set 1
week before RT.
Statistical Methods
The primary null hypothesis of this explorative study was
that, for PGS users, WHO gradeZ3 OM achieved after radi-
ation treatment should be lower than that achieved after the
same treatment in subjects treated by standard medical sup-
portive treatment. The current study was powered to determine
a decrease of 35% or greater in the WHO gradeZ3 OM for
PGS users with respect to nonusers. The literature indicates
that from 34% to 57% of patients with HNC and receiving RT
with or without chemotherapy experienced WHO grade 3/4
OM.4 Thus, we set the rate of WHO grade 3/4 OM in controls
at 50% (P0 = 50%). Using a 2-sided test and a 5% type I error,
with the matched control to case ratio of 1:4, 16 subjects in the
PGS groups and 64 in the control group would provide greater
than 80% power to detect a decrease of 35% (P1 = 15%). We
used an uncorrected w2 statistic to evaluate this null hypothesis.
To reduce treatment selection bias and determine treat-
ment effects, a case–control-matched propensity analysis was
performed. Multivariate logistic regression was used to cal-
culate the predicted probability of the dependent variables and
the propensity score for all observation in the data set. The
dependent variables included in the multivariate analysis were
listed in Table 1. A 1:4 matched analysis was performed where
1 case was matched to 4 controls. For the matched analysis,
differences between matched pairs were evaluated using t test
for paired data for continuous variables and the McNemar test
for binary data. Continuous variables were condensed by
means and SD. Differences in continuous variables were
analyzed by the Student t test or analysis of covariance. Binary
variables were condensed as absolute or relative frequencies.
Differences in dichotomous variables were analyzed by w2 test
or Fishers exact test when appropriate.
The odds that a patient treated with PGS in association
with standard supportive medical treatments will experience
WHO grade 3/4 toxicity as a function of time later than a
patient treated by supportive medical treatments alone have
been determined by the use of the Cox proportional hazard
model.
According to propensity analysis P-values <0.05 were
considered statistically significant. The SPSS version 13.0
software package was used for all statistical analysis and
graphic presentations.
RESULTS
Between October 2012 and January 2014, 35 consecutive
patients receiving RT with or without chemotherapy for HNC
were screened to be included in the study. Nineteen of the 35
subjects (55%) were excluded as they refused to participate in
the study (6/35; 17%), did not satisfy the inclusion criteria (3/
35; 9%), and did not match with any subject included in the
control group after propensity analysis (10/35; 29%). This
group was compared with an historical pool of patients (110
patients) treated between August 2004 and May 2012 with RT
with or without chemotherapy for HNC. Sixty-four of the 110
subjects (58%) were included in the study and were used as
controls. Eighteen of the 110 cases (16.3%) were excluded as
they did not match the inclusion criteria and 28 (25.5%) were
excluded as their propensity scores did not match with any of
the score of the subjects included in the PGS group.
All patients studied received platinum-based chemo-
therapy regimens and completed the treatment phase of the
study. The platinum doses or regimens were compar-
able between the 2 treatment groups. Forty-six percent (6/13) in
the PGS group and 55.6% (25/45) in the control groups
received intravenous cisplatin (40mg/m2) administered weekly
(P=0.753). Subjects treated with the standard supportive
medical treatment, 6% (4/64), 44% (28/64), 48% (31/64), and
6% (4/64) experienced WHO grade 1, 2, 3, and 4 OM,
respectively. Subjects treated by PGS in association with the
standard supportive medical treatment, 56% (9/16), 25% (4/16),
13% (2/16), and 6% (1/16) experienced grade 1, 2, 3, and 4
OM, respectively (Table 2). Interestingly, when the cutoff of
clinically significant toxicity was set at WHO grade 3/4, sub-
jects treated with standard supportive treatment experienced
significantly higher toxicity (55%; 35/64) than subjects treated
by PGS (13%; 3/16) (P= 0.012). The reduced toxicity found in
the group of patients treated by PGS paralleled with the evi-
dence that the onset of symptoms occurred at a later time than
in subjects who did not use PGS. The Cox proportional hazard
model indicated that patients treated with standard supportive
medical treatments experienced 2.7-fold increase (hazard
ratio = 2.7; 95% confidence interval, 1.3-5.7; P= 0.0074) in the
occurrence of WHO grade 3/4 toxicity than group treated by
PGS in association with standard supportive medical treatments
TABLE 2. WHO Score of Oral Mucosistis Upon Oncological
Treatments
Mucositis Severity Graded
as Recommended by WHO
PGS
Group
(N= 16)
(n [%])
Control
Group
(N= 64)
(n [%]) P*
0 0 (0) 0 (0) 1.0
1 9 (56) 4 (6) < 0.0001
2 4 (25) 28 (44) 0.254
3 2 (13) 31 (48) 0.012
4 1 (6) 4 (7) 1.0
Patients with WHO grade 3
and 4 toxicity
3 (19) 35 (55) 0.012
*Fisher exact test.
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(Fig. 1). In addition, patients treated by standard supportive
medical treatments alone experienced WHO grade 3/4 toxicity
before than PGS users (P=0.0074) (Fig. 1).
During RT, patients treated with PGS experienced a
significant lower weight loss (Fig. 2A) and need for feeding
tube (Table 3) compared with controls. Patients of both groups
were weighted 1 week before RT-CHT (baseline evaluation)
and then weekly during RT-CHT. The mean body weight of all
patients in each group was determined and it was plotted over
time to measure the changes of this parameter during
RT. Figure 2A shows that the loss of body weight in PGS users
was lower than controls after the sixth week of treatment and
this difference increased over time reaching the highest feet
apart at the end of radiation treatment (Fig. 2A). To investigate
if important clinical variables affected body weight loss, the
analysis of covariance test was performed. As shown
in Table 4 this analysis clearly indicated that all clinical var-
iables included in the model, except the kind of supportive
treatment, did not affect body weight loss suggesting that PGS
effectively impacted on body weight loss with respect to
standard supportive medical treatment. In addition, there was a
statistically significant difference in the opioid analgesics
usage in the group treated by PGS or by standard supportive
care (P= 0.0021) (Table 3). During RT, 19% of patients (3/16)
in the PGS group and 62.5% of patients (40/64) in the control
group did require narcotic medications (Table 3).
Finally, across the study period, PGS group significantly
experienced higher quality of life, as measured by OMWQ-HN
(Fig. 2B) (P< 0.001), and lower mouth and throat soreness
(Fig. 2C) (P< 0.001) with respect to controls. Interestingly, the
incidence of WHO grade 3/4 toxicity peaked just before
the worsening of quality of life measured by OMWQ-HN.
In the group treated by PGS, WHO grade 3/4 mucositis
appeared 28 days (mean, 31 ± 2.6 d) after beginning of radia-
tion course. In the control group the same toxicity appeared 21
days (25.8 ± 3 d) after beginning of radiation course with a
significant difference (P = 0.016) with respect to PGS group.
The higher toxicity found in the control group paralleled with
longer duration of radiation course with respect to PGS groups
(52.3 ± 4.5 vs. 49.5 ± 5.1 d) (P= 0.03). In this regard, a total of
2 patients (12.5%) and 18 patients (28.1%) temporarily dis-
continued radiation treatment for 5 or more consecutive frac-
tions in the PGS and control groups, respectively. Four patients
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FIGURE 1. Kaplan-Meier plot of time to onset of severe oral
mucositis (WHO grade 3/4) by treatment group.
TABLE 3. Narcotic Analgesic and Tube Feeding Use in Patients
Treated or Untreated with PGS
PGS Group
(N= 16) (n [%])
Control Group
(N= 64) (n [%]) P*
Opioid analgesics use
Requiring 3 (19) 40 (62.5) 0.0021
None 13 (81) 24 (37.5)
Feeding tube
Requiring 2 (12) 13 (20.3) 0.72
None 14 (88) 51 (79.7)
*Fisher exact test.
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FIGURE 2. Body weight loss of patients treated (PGS) or not
(control) with PGS during the radiation course (A). OMWQ-HN
mean scores (B) and mouth and throat soreness (MTS) assess-
ment (C) during radiation treatment.
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(6.2%) in the control group and none in the PGS group dis-
continued radiation treatment for a total of 10 or greater
radiation doses.
The safety profile of PGS administered concomitantly
with standard supportive medical treatment was comparable
with that of standard supportive medical treatment alone. PGS
oral administration was generally well tolerated. A number of
subjects reported 1 or more treatment-emergent adverse event
related to chemotherapy. Adverse events included: (i) neph-
rotoxicity (6.2%, 5/80) (elevations in BUN and creatinine), (ii)
ototoxicity (1.2%, 1/80) (tinnitus), (iii) mild to moderate
myelosuppression (19%, 15/80), (iv) nausea and vomiting
(51.2%, 41/80). The events were resolved spontaneously
without sequelae or by specific supportive medical treatment.
There was no local tolerance issue, deaths, or serious adverse
events in the study.
DISCUSSION
Despite multimodal prophylaxis and therapy, radio-
induced OM often takes a therapeutically refractory turn
necessitating the use of topical and systemic analgesics.5,6 So,
it is essential to identify new strategies that quickly counteract
the mucositis progression improving patients’ quality of life
and treatment compliance. In this study, we demonstrate that
PGS when administered in association with standard suppor-
tive medical treatment topically to the oral mucosa as a pro-
phylactic treatment decreased the incidence and severity of
clinically significant OM in a cohort of subjects suffering from
HNC and treated by RT with or without chemotherapy. Top-
ical PGS treatment substantially reduced the development of
severe OM (WHO gradeZ3) of the study cohort in a manner
consistent. The incidence of WHO grade 4 OM was com-
parable between 2 study groups suggesting that PGS effec-
tively decreased WHO grade 3 OM. The evidence that PGS
results in a preferential decrease of WHO grade 3 OM may not
have an univocal interpretation. Surely the low number of
subjects within each subgroup stratified according to WHO
toxicity score may explain the lack of statistical significance
with respect to grade 4 toxicity. The onset of clinically sig-
nificant severe OM (WHO gradeZ3) in PGS users was moved
forward in time with respect to subjects treated by standard
medical supportive treatment. The Cox proportional hazard
model indicated that PGS users in association with standard
medical supportive treatment experienced WHO gradeZ3
later than subjects treated by standard medical supportive
treatment alone. In addition, PGS users experienced 2.7-fold
decrease (95% confidence interval, 1.31-5.7; P = 0.0074) in the
risk for severe OM during radiation course with respect to
nonuser. The impact of PGS on OM onset was probably due to
the effect that this treatment may exert an epithelial cell pro-
liferation of the oral mucosa. It is well known that PGS reg-
ulates tissue homeostasis and favors the release of biological
factors able to promote tissue repair and angiogenesis.7,8 The
observed reduction in the maximum severity of OM between
PGS users and nonusers had an evident impact on the need for
opioid use. These data paralleled with the findings that the
higher toxicity found in the control group paralleled with
longer duration of radiation course with respect to PGS users.
In addition, a lower body weight loss in the group treated with
PGS was found with respect to controls. The severity of
mucositis adversely impacted on the quality of life of patients
treated with the only standard supportive medical treatment.
The use of PGS in association with standard supportive care
treatment resulted in a significant improvement in quality of
life as attested by the use of specific standardized measures.
From a methodological point of view, the most interesting
strength point of our explorative study was the use of pro-
pensity score analysis. The propensity score is the probability
of treatment assignment conditional on observed baseline
characteristics. This statistical analysis allows one to design
and analyze an observational (nonrandomized) study so that it
mimics some of the particular characteristics of a randomized
controlled trial. In particular, the propensity score is a bal-
ancing score: conditional on the propensity score, the dis-
tribution of observed baseline covariates will be similar
between treated and untreated subjects. So, the use of this
powerful methodological approach allowed us to improve the
soundness of obtained evidence.
With respect to toxicity ascribable to PGS, the literature
does not report specific data in this regard. In our study the oral
toxicity found among PGS users was judged as not being
caused by PGS as the kind of local toxicity seemed clearly
related to chemotherapy or RT. Concerning the possible effect
of PGS on the incidence of systemic adverse events our data
seem to confirm that PGS administration is associated with a
good toxicity profile as no difference in the rate systemic
toxicity between the 2 groups was found. Although we cannot
definitively exclude that PGS may adversely affect oral func-
tion or have systemic effects this treatment seems to positively
TABLE 4. Impact of Clinical Variables on Body Weight Loss Determined by Analysis of Covariance
Confounding Factors Sum of Squares df Mean Square F P
Chemotherapy use 2.210 1 2.210 0.374 0.543
RT dose 3.220 1 3.220 0.545 0.463
Stage grouping 0.0395 1 0.0395 0.00669 0.935
Age 2.123 1 2.123 0.326 0.521
Sex 0.0123 1 0.0123 0.00233 0.821
Site 0.0231 1 0.0231 0.00345 0.844
Treatments 520.726 1 520.726 88.120 < 0.001
Coefficient of determination R2 0.5698
R2-adjusted 0.5444
Pairwise Comparisons
Variables Mean Difference SE P* 95% CI*
PGS groups vs. Control groups 6.6272 0.7060 < 0.0001 5.2208-8.0336
*Bonferroni corrected.
ANCOVA indicates analysis of covariance; CI, confidence interval; df, degrees of freedom; PGS, platelet gel supernatant; RT, radiotherapy.
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affect the clinical course of subjects with radio-induced OM
with respect to non-PGS users.
Several limitations affect our study. The main ones are
the small sample size and the use of a nonrandomized study
design. To date, large randomized controlled trials have pro-
vided the strongest evidence for the efficacy of therapeutic
procedures or treatments in the clinical setting. However, this
bias has been mitigated by the use of a strategy based on
propensity score analysis, which helped us to obtain 2 groups
of patients virtually randomized for important clinical char-
acteristics. Thus, comparative analysis by propensity-matched
pairs contributed to the results being less prone to method-
ological biases than other usual statistical methods. With
respect to the small sample size, the main influence of this
parameter on the quality of a clinical study concerns the stat-
istical power. If the sample size declines, the power also
declines. Thus, if the sample size of a study is too small, the
power of a study may be low to the point of unreliably showing
the traits that are sought by the researcher.
Another limit concerns the study protocol used. Radiation
toxicity may further get worse after RT and a treatment
strategy based on the use of PGS both during and after RT
instead of a strategy based on an administration during RT
could configure as more effective in reducing radio-induced
OM. So our study may have underestimated the beneficial
effects of PGS on the radio-induced OM.
Finally, all radiation treatments were performed by a 3D-
conformal approach which, although is considered a standard
of treatment in HNC, toxicity may be higher than with IMRT.
In this regard, the use of PGS during IMRT may have a lesser
clinical impact than with other radiation approaches.
Although the observational nature of our study means that
our results have to be interpreted with caution, we found that
PGS used in association with supportive medical treatments is
a new, potentially beneficial, medical device in the manage-
ment of OM induced by chemo-RT. These preliminary data
should be interpreted with caution and could serve as a
framework around which to design future trials.
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